ANGLE PLC S/ADR - ANPCY STOCK NEWS

ANGLE plc (OTCQX: ANPCY) announced the issuance of 20,000 new ordinary shares following the exercise of employee options, raising the total number of shares to 235,136,384. These shares will commence trading on the London Stock Exchange's AIM on December 7, 2021. The shares rank equally with existing shares. ANGLE focuses on liquid biopsy solutions with its Parsortix system, which captures circulating tumor cells for analysis, supporting advances in cancer diagnostics.

ANGLE plc announces the publication of research from the Medical University of Vienna, demonstrating the effectiveness of its Parsortix system in analyzing circulating tumor cells (CTCs) in non-small cell lung cancer (NSCLC) patients. The study reveals that CTCs with cancer stem cell properties correlate with worse patient outcomes. The Parsortix system achieves a capture rate of up to 80%, surpassing competing systems, and supports RNA analysis for prognostic purposes. The research underscores the potential of CTCs in clinical management and drug discovery.

ANGLE plc announced the issuance of 50,000 new ordinary shares following the exercise of employee options. This move will increase the total number of ordinary shares to 235,116,384. The new shares are set to be admitted to trading on AIM, with the start date expected to be December 2, 2021. ANGLE's Parsortix® system, a key technology for liquid biopsy, is under FDA review for use in metastatic breast cancer patients, while a successful clinical study for an ovarian cancer triage test showed remarkable 95.1% accuracy.

ANGLE plc (OTCQX:ANPCY) has issued 22,667 new ordinary shares following the exercise of employee options, increasing its total shares to 235,066,384. These shares will rank equally with existing shares, and trading is set to commence on November 23, 2021. The company is known for its liquid biopsy technologies, specifically the Parsortix system, which harvests circulating tumor cells (CTCs) for cancer analysis. ANGLE's advancements in cancer diagnostics and established collaborations with renowned medical institutions support its innovative approaches in healthcare.

ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has appointed Todd Druley, M.D., PhD as Chief Medical Officer, based in the U.S. Dr. Druley, a prominent oncologist with significant experience in molecular diagnostics, previously served at ArcherDX, which was acquired for up to $1.4 billion. His expertise will guide ANGLE's diagnostics development, regulatory processes, and commercial strategies, particularly enhancing the Parsortix system's applications. ANGLE aims to launch its first laboratory-developed test and expand its clinical market offerings.

ANGLE plc (OTCQX: ANPCY) announced the approval of 3,000,000 LTIP options and 4,942,500 staff share options under its existing plans. These options are designed to enhance shareholder value, tied to performance metrics over three years. As of now, the company holds options over 32,406,146 Ordinary Shares, approximately 12.1% of its share capital. The share options will have specific performance conditions and will vest based on the CAGR of share price. The expiration date for certain existing options has been extended to November 17, 2022.

ANGLE plc (OTCQX:ANPCY) has issued 70,000 new ordinary shares following the exercise of employee options. These shares, valued at £0.10 each, will rank pari passu with existing shares and are set to be admitted to AIM on November 18, 2021. This raises the total number of ordinary shares to 235,043,717. ANGLE specializes in liquid biopsy technologies, focusing on cancer diagnostics, and aims for FDA clearance for its Parsortix system, which has shown promising results in clinical trials for metastatic breast cancer and ovarian cancer.

ANGLE plc (OTCQX:ANPCY) will present at the Jefferies London Healthcare Conference on November 16 at 10:00 AM GMT. The conference is the largest healthcare-focused investor event in Europe and features CEO Andrew Newland and CFO Ian Griffiths. ANGLE's innovative Parsortix liquid biopsy technology enables comprehensive cancer analysis through non-invasive blood tests, with a CE Mark in Europe and a pending FDA submission for breast cancer applications. The company is advancing clinical studies to enhance ovarian cancer detection accuracy.

ANGLE plc (OTCQX:ANPCY) presented findings at the NCRI Festival indicating that longitudinal analysis of circulating tumor cells (CTCs) using the Parsortix system can effectively predict treatment response in metastatic prostate cancer patients undergoing docetaxel therapy. The study revealed that the KLK2 gene expression on CTCs was a more reliable biomarker for assessing cancer progression than current PSA levels. This non-invasive method could allow for early detection of treatment resistance, improving patient outcomes by enabling timely treatment adjustments, as prostate cancer rates continue to rise significantly.